REFERENCES
1. Merte B. [The first general mathematical description of optical
lenses without aberrations]. Klinische Monatsblatter fur
Augenheilkunde 1989;194(1):59-61.
2. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y,
Nagataki S. Early recognition of hepatocellular carcinoma based on
altered profiles of alpha-fetoprotein. N Engl J Med
1993;328(25):1802-1806.
3. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and
Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology
2016;150(4):835-853.
4. Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment.
World J Hepatol 2015;7(10):1377-1389.
5. Carrozzo M, Scally K. Oral manifestations of hepatitis C virus
infection. World J Gastroenterol 2014;20(24):7534-7543.
6. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies.
World J Gastroenterol 2014;20(24):7544-7554.
7. Montenegro L, De Michina A, Misciagna G, Guerra V, Di Leo A. Virus C
hepatitis and type 2 diabetes: a cohort study in southern Italy. Am J
Gastroenterol 2013;108(7):1108-1111.
8. Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, Brown EL, Engels EA.
Hepatitis C virus infection and the risk of cancer among elderly US
adults: A registry-based case-control study. Cancer
2017;123(7):1202-1211.
9. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ.
Lifetime risk and sex difference of hepatocellular carcinoma among
patients with chronic hepatitis B and C. J Clin Oncol
2011;29(27):3643-3650.
10. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular
carcinoma. Gastroenterology 2012;142(6):1264-1273 e1261.
11. Parkin DM. The global health burden of infection-associated cancers
in the year 2002. Int J Cancer 2006;118(12):3030-3044.
12. Tholey DM, Ahn J. Impact of Hepatitis C Virus Infection on
Hepatocellular Carcinoma. Gastroenterol Clin North Am
2015;44(4):761-773.
13. Weng G, Bhalla US, Iyengar R. Complexity in biological signaling
systems. Science 1999;284(5411):92-96.
14. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC,
Sun TH, Tu SJ, Lee WH, Chiew MY, Tai CS, Wei TY, Tsai TR, Huang HT, Wang
CY, Wu HY, Ho SY, Chen PR, Chuang CH, Hsieh PJ, Wu YS, Chen WL, Li MJ,
Wu YC, Huang XY, Ng FL, Buddhakosai W, Huang PC, Lan KC, Huang CY, Weng
SL, Cheng YN, Liang C, Hsu WL, Huang HD. miRTarBase update 2018: a
resource for experimentally validated microRNA-target interactions.
Nucleic Acids Res 2018;46(D1):D296-D302.
15. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G,
Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K,
Kalfakakou D, Fevgas A, Dalamagas T, Hatzigeorgiou AG. DIANA-TarBase
v7.0: indexing more than half a million experimentally supported
miRNA:mRNA interactions. Nucleic Acids Res 2015;43(Database
issue):D153-159.
16. Tong Z, Cui Q, Wang J, Zhou Y. TransmiR v2.0: an updated
transcription factor-microRNA regulation database. Nucleic Acids Res
2019;47(D1):D253-D258.
17. Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A,
Baron M, Sanz F, Furlong LI. DisGeNET: a discovery platform for the
dynamical exploration of human diseases and their genes. Database
(Oxford) 2015;2015:bav028.
18. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu
Y. miR2Disease: a manually curated database for microRNA deregulation in
human disease. Nucleic Acids Res 2009;37(Database issue):D98-104.
19. Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, Zhou Y, Cui Q. HMDD
v3.0: a database for experimentally supported human microRNA-disease
associations. Nucleic Acids Res 2019;47(D1):D1013-D1017.
20. Nibbe RK, Koyuturk M, Chance MR. An integrative -omics approach to
identify functional sub-networks in human colorectal cancer. PLoS Comput
Biol 2010;6(1):e1000639.
21. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C,
Kim IF, Soboleva A, Tomashevsky M, Marshall KA, Phillippy KH, Sherman
PM, Muertter RN, Edgar R. NCBI GEO: archive for high-throughput
functional genomic data. Nucleic Acids Res 2009;37(Database
issue):D885-890.
22. Wang Z, Jensen MA, Zenklusen JC. A Practical Guide to The Cancer
Genome Atlas (TCGA). Methods Mol Biol 2016;1418:111-141.
23. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009;4(1):44-57.
24. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the
growth of hepatocellular carcinoma by stimulating canonical Wnt
signaling. Cancer Res 2005;65(14):6245-6254.
25. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK
expression and activity in primary human hepatocellular carcinoma.
Biochem Biophys Res Commun 1997;236(1):54-58.
26. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF,
Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1
polymorphisms and susceptibility to hepatocellular carcinoma.
Gastroenterology 1995;109(4):1266-1273.
27. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential
link between non-alcoholic fatty liver disease and hepatocellular
carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut
2016;65(11):1850-1860.
28. Cheng YQ, Ren JP, Zhao J, Wang JM, Zhou Y, Li GY, Moorman JP, Yao
ZQ. MicroRNA-155 regulates interferon-gamma production in natural killer
cells via Tim-3 signalling in chronic hepatitis C virus infection.
Immunology 2015;145(4):485-497.
29. Riad SE, El-Ekiaby N, Mekky RY, Ahmed R, El Din MA, El-Sayed M,
Abouelkhair MM, Salah A, Zekri AR, Esmat G, Abdelaziz AI. Expression
signature of microRNA-155 in hepatitis C virus genotype 4 infection.
Biomed Rep 2015;3(1):93-97.
30. Li S, Sun S, Yu S, Dong Z, Jiang K, Xiang L, Li H. Association
between EZH2 Genetic Variants and Hepatocellular Carcinoma in a Chinese
Han Population. Clin Lab 2018;64(1):85-91.
31. Liu H, Liu Y, Liu W, Zhang W, Xu J. EZH2-mediated loss of miR-622
determines CXCR4 activation in hepatocellular carcinoma. Nat Commun
2015;6:8494.
32. Khairy A, Hamza I, Shaker O, Yosry A. Serum miRNA Panel in Egyptian
Patients with Chronic Hepatitis C Related Hepatocellular Carcinoma.
Asian Pac J Cancer Prev 2016;17(5):2699-2703.
33. El Tayebi HM, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI.
Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of
IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett
2015;10(5):3206-3212.
34. Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y, Tian T.
MicroRNA-155-5p promotes hepatocellular carcinoma progression by
suppressing PTEN through the PI3K/Akt pathway. Cancer Sci
2017;108(4):620-631.
35. Li DP, Fan J, Wu YJ, Xie YF, Zha JM, Zhou XM. MiR-155 up-regulated
by TGF-beta promotes epithelial-mesenchymal transition, invasion and
metastasis of human hepatocellular carcinoma cells in vitro. Am J Transl
Res 2017;9(6):2956-2965.
36. Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K,
Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y,
Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S,
Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A,
Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T,
Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in
Japanese patients with nonalcoholic fatty liver disease and alcoholic
liver disease: multicenter survey. J Gastroenterol 2016;51(6):586-596.